Abstract: FR-PO616

The Impact of Glucagon-Like-Peptide-1on JAK-STAT Pathway in Diabetic Kidney Disease in db/db Mice and in Endothelial Cells Exposed to a Diabetic Environment

Session Information

Category: Diabetes

  • 501 Diabetes Mellitus and Obesity: Basic - Experimental

Authors

  • Einbinder, Yael, Meir Medical Center, Kfar Saba, Kfar Saba, Center, Israel
  • Benchetrit, Sydney, Meir Medical Center, Kfar Saba, Israel
Background

The Janus kinase/signal transducer and transcription activator (JAK/STAT) proteins mediate the actions of many cytokines, chemokines, hormones, and growth factors critical to cell proliferation, differentiation, migration, and apoptosis. This study used db/db mice and endothelial cells (EC) to determine the effect of a diabetic environment on the JAK-STAT pathway, and to assess the potential effect of GLP-1 analogue in both models.

Methods

C57BL/6 (WT) and BKS.Cg-Dock7m +/+ Leprdb/db (db/db) mice were randomized to WT group, db/db mice (diabetic control group) and db/db mice treated with GLP-1 analog (Liraglutide) for 14 weeks. The kidneys were then perfused and removed for mRNA, protein analysis and Immunohistochemistry. EC obtained from Human umbilical vein were stimulated with AGE-HSA, glucose and GLP-1 for 24 hours.

Results

p-STAT3 (Ser 727) and p-STAT3 (Tyr 705) were significantly up-regulated in control db/db mice compared to WT mice. GLP-1 analog significantly down-regulated p-STAT3 (Ser 727, Tyr 705) protein expression compared to control db/db mice. P-STAT3 was mainly expressed in the glomeruli, while p-JAK2 was expressed in the tubules also. In EC stimulated with diabetic environment p-STAT3 (Tyr 705) and JAK2 were up regulated while GLP-1 analog significantly down-regulated there expression. The GLP-1 analog inhibited the target gene SIRT1 in db/db mice and in EC culture.

Conclusion

JAK-STAT pathway is activated in experimental models of diabetes mellitus. The GLP-1 analogue (liraglutide) inhibited STAT3 and JAK2 expression in db/db mice and in EC culture possibly through inhibition of SIRT1.